Core Viewpoint - WuXi AppTec (02268) has announced a share placement agreement to raise approximately HKD 1.3 billion, primarily aimed at expanding its service capacity and production capabilities in bioconjugates and active pharmaceutical ingredients [1] Group 1: Share Placement Details - The company has signed a placement agreement with underwriters to fully underwrite up to 22.77 million shares at a price of HKD 58.85 per share, expecting net proceeds of about HKD 1.3 billion [1] - Approximately 90% of the raised funds will be allocated to enhance the group's service capacity and production capabilities, particularly in bioconjugates, active pharmaceutical ingredients, and clinical and commercial production [1] - The remaining 10% of the funds will be used for working capital and general corporate purposes [1] Group 2: Subscription Agreement - WuXi AppTec has also entered into a subscription agreement with its controlling shareholder, WuXi Biologics (02269), to issue 24.134 million subscription shares at the same price of HKD 58.85 per share, with net proceeds expected to be around HKD 1.4 billion [1] - Similar to the placement, about 90% of the subscription proceeds will be directed towards further expanding the group's service capacity and production capabilities, including bioconjugates and active pharmaceutical ingredients [1] - The remaining 10% will be allocated for the group's working capital needs and general corporate purposes [1]
港股异动 | 药明合联(02268)早盘涨超5% 公司宣布配股筹资 控股股东药明生物斥资超14亿港元认购